Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Raleigh Capital Management Inc.

Raleigh Capital Management Inc. decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,737 shares of the medical instruments supplier’s stock after selling 55 shares during the period. Raleigh Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $394,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of BDX. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company in the third quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $33,000. Tompkins Financial Corp boosted its holdings in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares in the last quarter. Sound Income Strategies LLC grew its position in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the period. Finally, Kennebec Savings Bank purchased a new position in Becton, Dickinson and Company in the third quarter valued at about $46,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 1.0 %

Becton, Dickinson and Company stock opened at $238.05 on Thursday. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The stock has a market cap of $69.04 billion, a PE ratio of 40.08, a P/E/G ratio of 1.74 and a beta of 0.39. The stock has a 50-day moving average price of $227.44 and a 200 day moving average price of $232.83. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $248.42.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the company earned $3.42 earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. Equities research analysts predict that Becton, Dickinson and Company will post 14.42 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 9th were issued a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend was Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.75%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Evercore ISI boosted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $283.50.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total value of $185,180.00. Following the completion of the transaction, the executive vice president now owns 16,201 shares in the company, valued at $3,807,235. This represents a 4.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock valued at $2,210,716 over the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.